Name: AXPAXLI (axitinib intravitreal implant) in Neovascular age-related macular degeneration: Generic, brand name and therapeutic class of product
Published: 2026-09-17T18:54:38-04:00

Product information and disease description Product description Product information

Generic, brand name and therapeutic class of product

5 evidence topics · 4 sources

Manufacturer: Ocular Therapeutix

“Sponsor Ocular Therapeutix, Inc.” (opens the source at this quote in a new tab)

Product names and development code

“AXPAXLI™ (also known as OTX-TKI), Ocular’s investigational product candidate for retinal disease, is an axitinib intravitreal hydrogel based on its ELUTYX™ proprietary bioresorbable hydrogel-based formulation technology.” (opens the source at this quote in a new tab)

Intervention name in trial registrations

“Drug: OTX-TKI (axitinib implant)” (opens the source at this quote in a new tab)

Therapeutic class

“Our product candidate AXPAXLI is an investigational, bioresorbable hydrogel implant, based on our ELUTYX technology, incorporating axitinib, a small molecule, multi-target, tyrosine kinase inhibitor, or TKI, with anti-angiogenic properties.” (opens the source at this quote in a new tab)

Class context: approved oral axitinib

“INLYTA (axitinib) is a kinase inhibitor.” (opens the source at this quote in a new tab)

Nonproprietary name for the implant

No evidence found.